All posts by admin

Business Wire India

Univastu India Limited announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The company posted consolidated revenue of INR 243.35 crore for FY26, up from INR 171.18 crore in FY25 — a year-on-year increase of 42.16%. EBITDA rose to INR 41.61 crore at a margin of 17.10%, while Net Profit advanced 65.55%to INR 25.69 crore.

The fourth quarter capped the year on a strong note, with Q4 FY26 revenue rising 174.23% year-on-year to INR 109.44 crore on the back of accelerated project execution and robust order conversions in the second half.

Consolidated Financial Highlights – FY26 & Q4 FY26

 

Particulars (INR in Crore)	Q4 FY25	Q4 FY26	Y-o-Y %	FY25	FY26	Y-o-Y %
Revenue from Operations	39.91	109.44	174.23%	171.18	243.35	42.16%
EBITDA	8.25	15.26	85.02%	29.14	41.61	42.78%
EBITDA Margin (%)	20.67%	13.94%	—	17.03%	17.10%	—
Net Profit (PAT)	4.21	10.33	145.13%	15.52	25.69	65.55%
PAT Margin (%)	10.56%	9.44%	—	9.07%	10.56%	—

 

Sequential Performance – Q4 FY26 vs Q3 FY26

 

Particulars (INR in Crore)	Q3 FY26	Q4 FY26	Q-o-Q %
Revenue from Operations	56.16	109.44	94.88%
EBITDA	10.19	15.26	49.83%
EBITDA Margin (%)	18.14%	13.94%	—
Net Profit (PAT)	6.03	10.33	71.21%
PAT Margin (%)	10.74%	9.44%	—

 

Operational Highlights – FY26

Incorporated in 2009 and headquartered in Pune, Maharashtra, Univastu India Limited is an integrated Engineering, Procurement, and Construction (EPC) company specialising in civil and structural construction and infrastructure development. Serving both the public and commercial sectors, the company has established a strong track record across specialised verticals spanning metro infrastructure, commercial structures, hospitals, cold storages, educational institutions, and sports complexes.

1. Revenue from operations grew 42.16% year-on-year to INR 243.35 crore, powered by strong execution across infrastructure and specialised construction verticals, including metro rail electrical power supply (OHE) and station E&M works.

2. The sports infrastructure segment emerged as a key growth driver, with the company executing stadiums, sports complexes, and allied recreational facilities for public and institutional clients — positioning Univastu to capitalise on rising public investment in sporting and community infrastructure across India.

3. Net Profit climbed 65.55% to INR 25.69 crore, underpinned by stronger project margins and improved operational efficiency.

4. EBITDA expanded 42.78% to INR 41.61 crore, with margins holding firm at 17.10% — a clear marker of consistent execution quality.

5. Q4 FY26 was the standout quarter of the year, delivering revenue of INR 109.44 crore — up 174.23% year-on-year and 94.88% sequentially — driven by accelerated project completions and billing.

6. The company further broadened its project pipeline across government infrastructure, metro works, hospitals, sports and recreational facilities, and institutional construction, strengthening its position as a diversified EPC player.

 

Management Commentary

Commenting on the performance, Dr. Pradeep Khandagale, Chairman & Managing Director of Univastu India Limited, said: “FY26 has been a defining year for Univastu India Limited. Revenue growth of 42.16% and a 65.55% rise in net profit are a direct outcome of the strength of our order book, the discipline and consistency of our project teams, and the enduring trust our clients place in us across both the public and private sectors. The standout performance in Q4 underscored our ability to scale execution without compromising on quality or margins. Importantly, FY26 also marked meaningful progress in newer growth verticals — most notably our sports and recreational infrastructure segment, alongside metro rail electrical systems — broadening the foundation on which we will build. As we look ahead, we remain committed to building a resilient, sustainable EPC business across civil infrastructure, metro, healthcare, sports, and institutional segments, and are well positioned to capitalise on India’s expanding pipeline of public infrastructure investment.”

Business Wire India

Business Wire India

E Factor Experiences Limited (NSE SME: EFACTOR), one of India’s leading large-scale event execution and experiential infrastructure companies, today announced its audited financial results for the year ended March 31, 2026. The Board of Directors approved the audited Standalone and Consolidated Financial Results at its meeting held on Tuesday, May 26, 2026, in Noida. The year was marked by solid top-line growth, strategic investment in in-house capability, and a step-change in the scale and quality of opportunities entering the order book.

 

Key Financial Summary – FY26 vs FY25

 

Consolidated (INR Crore)	FY26	FY25	Change
Revenue from Operations	191.44	171.51	+11.6%
Profit After Tax	19.67	20.17	−2.5%
Net Worth	90.32	72.80	+24.1%
Current Ratio (x)	2.08	1.78	+0.30x
Subsidiary – Adventure Tourism PAT	1.32	0.03	+3,900%

Standalone core business revenue increased 10.1% to INR 180.20 crore. Figures based on audited results; INR in Crore converted from figures reported in INR Lacs.

Performance Highlights

Revenue Growth Despite Headwinds: Consolidated Revenue from Operations grew 11.6% to INR 191.44 crore, reflecting strong underlying demand and the Company’s ability to win and execute larger, more complex mandates. Top-line performance could have been materially higher but for the geopolitical disruption in West Asia, which led to the postponement or cancellation of approximately INR 35-40 crore of confirmed business in-year.

A Deliberate Year of Investment: The modest 2.5% moderation in Consolidated PAT to INR 19.67 crore reflects deliberate reinvestment, not operational weakness. Employee Benefit Expenses rose 11.7% as the Company expanded its in-house team to 75+ across five disciplines; depreciation and finance costs rose in step with investment in fixed assets and project-execution working capital. These are the foundations of FY27 delivery capacity.

Strong Liquidity Position: The Consolidated Current Ratio improved to 2.08x (from 1.78x) and Consolidated Net Worth grew 24% to INR 90.32 crore. The Company is focused on accelerating collections and improving its Debt Service Coverage through milestone-linked billing on all future large-scale projects.

Experiential Tourism – A Breakout Year: Wholly-owned subsidiary E Factor Adventure Tourism Pvt. Ltd. delivered revenue of INR 11.23 crore with Profit After Tax surging 3,900% to INR 1.32 crore, operating curated adventure and cultural tourism experiences at iconic destinations including Jaipur, Hampi, Tamil Nadu and Telangana.

Riding India’s Orange Economy Wave

The performance is anchored by a powerful policy tailwind. The Hon’ble Prime Minister, at the Viksit Bharat Young Leaders Dialogue in January 2026, noted that India’s creative economy – driven by culture, content and innovation – is “positioning the country as a global leader in emerging sectors.” The Union Budget 2026 placed the “Orange Economy” at the centre of the national agenda, targeting 2 million AVGC jobs by 2030 alongside nationwide creative-economy labs.

E Factor is among the very few listed pure-play vehicles through which public investors can participate in this theme, operating across all six strategic verticals the national vision identifies: cultural infrastructure, immersive experiences, experiential tourism, live entertainment, heritage redevelopment, and owned intellectual property.

FY27 Outlook – A Pipeline Built for the Next Level

E Factor enters FY27 with the strongest pipeline in its history – a qualified opportunity base of over INR 500 crore, against which management is targeting a measured 60% conversion. The pipeline is weighted towards permanent installations, immersive museums, heritage redevelopment and cultural experience centres, with 18-36 month delivery cycles and higher ticket sizes.

From Event Fees to Annuity Revenue: Every large permanent installation is being structured to include a long-term Operations & Maintenance relationship, converting one-time project revenue into recurring, high-visibility annuity income. This improves revenue predictability, deepens client relationships, and positions the Company for a re-rating as the annuity layer grows.

Building India’s Most Distinctive IP Portfolio

Shiva Immersive – Global Recognition: The Company’s flagship owned IP, Shiva Immersive – a daily-ticketed immersive cultural experience – was recognised at the WXO World Experience Summit during London Experience Week 2026, the global gathering of the $13 trillion experience economy, earning its place on the world stage as an originally-Indian immersive format.

Entry into Concert Touring: E Factor served as co-promoter for the India leg of Dream Theater’s 40th Anniversary World Tour (Bengaluru and Kolkata, January-February 2026) – the GRAMMY-winning band’s first India shows in nearly a decade. The profit-positive engagement marks the Company’s deliberate entry into the global concert touring business.

Bridal Retreat & EDS: The Company is piloting Bridal Retreat, a scalable premium destination-wedding format, and will this year host the Experience Design Summit (EDS) in India – a first-of-its-kind inbound convening that brings the world’s leading experience designers to Bharat.

Management Commentary

“FY26 was, by design, a year of building. We chose to absorb a difficult external shock rather than chase short-term profit, and we used the year to deepen our in-house team, sharpen our IP portfolio, and qualify the largest pipeline in our history. The Shiva Immersive recognition in London, our entry into concert touring with Dream Theater, and EDS bringing the world to Bharat – these are early signals of what E Factor is becoming.”   Samit Garg – Managing Director, E Factor Experiences Limited

 

“The financials tell a disciplined story. We grew the top line 11.6% in a year that cost us INR 35-40 Crore in postponed mandates, while strengthening our Current Ratio to 2.08x and Net Worth to INR 90 Crore.   From FY27, now that we have spent 25 years learning how to render India’s public imagination, the next 5 years and after will be about doing it at a scale that matters – building places where the world will visit, bring their children, feel something, and carry their emotion forward. Every large project will carry milestone-linked billing and concentration safeguards – protecting margins, accelerating collections, and improving Debt Service Coverage. The investment phase is behind us; the focus now shifts decisively to translating our pipeline into profitable, predictable revenue and delivering compounding value to our shareholders.”   Jai Thakore – Chairman, E Factor Experiences Limited

 

Business Wire India

The Fortegra Group, Inc. (“Fortegra”), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. (“DB”), one of Korea’s leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals.

 

Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience.

 

 

Richard Kahlbaugh, Chairman and CEO of Fortegra, said: “Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance and Fortegra intend to build a recognized leader in the global specialty insurance market.”

 

 

About Fortegra

 

 

For more than 45 years, Fortegra, via its subsidiaries, has underwritten risk management solutions that help people and businesses succeed in the face of uncertainty. As a multinational specialty insurer whose insurance subsidiaries have an A.M. Best Financial Strength Rating of A- (Excellent) and an A.M. Best Financial Size Category of ‘X’, we offer a diverse set of admitted and excess and surplus lines insurance products and warranty solutions. For more information: www.fortegra.com.

 

 

About DB Insurance

 

 

For more than six decades, DB Insurance Co., Ltd. has built a strong foundation as one of Korea’s leading insurers, protecting individuals and businesses while driving the advancement of the nation’s insurance industry. Founded in 1962 as Korea’s first public automobile insurer, the company adopted the name DB Insurance in 2017 to embody its vision of becoming a global insurance group. With an A.M. Best Financial Strength Rating of A+ (Superior) with Financial Size Category of ‘XV’ and S&P Rating A+ (Stable), DB Insurance provides a comprehensive portfolio of general, long-term, and automobile insurance, along with a broad range of financial services through its subsidiaries in life insurance, securities, savings banking, and asset management. For more information: www.idbins.com.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528048583/en/

 

Business Wire India

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

 

The Notification Letter also stated that the Company will be subject to a mandatory panel monitor (the “Panel Monitor”) for a period of one year from the date of such letter. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Periodic Filing Rule that was the subject of the exception, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Panel if the initial Panel is unavailable. The Company will have the opportunity to respond and present to the Panel as provided by Nasdaq Listing Rule 5815(d)(4)(C).

 

 

Subsequently, the Company received a delist determination letter (the “Staff Determination”) from Nasdaq dated May 22, 2026, stating that because the Company has not timely filed its annual report on Form 20-F for the year ended December 31, 2025 (the “2025 Annual Report”), the Company no longer complies with the Periodic Filing Rule. Therefore, in accordance with the Panel Monitor, unless the Company timely requests a hearing before the Panel regarding the Staff Determination by May 29, 2026, the Company’s securities would be subject to suspension and delisting.

 

 

Accordingly, the Company has today requested a hearing before the Panel. Such hearing request automatically stays the suspension of the Company’s securities for a period of 22 calendar days from the date of the Staff Determination. The Company has also requested a further stay of any suspension action pending the completion of the hearing process.

 

 

About SINOVAC

 

 

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

 

 

The Company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive^®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

 

 

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu^®), the world’s first H1N1 influenza vaccine (Panflu.1^®), and CoronaVac^®, the most widely used inactivated COVID-19 vaccine globally.

 

 

Beyond its marketed portfolio, the Company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

 

 

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the Company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

 

 

For more information, please see the Company’s website at www.sinovac.com.

 

 

Safe Harbor Statement

 

 

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, including the Company’s statements related to the timing and actions taken to regain compliance with Nasdaq listing rules. Such statements are based upon the Company’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the completion and filing of the 2025 Annual Report, and actions taken to regain compliance with the Nasdaq listing rules, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529895816/en/

 

Business Wire India

India’s leading natural pet wellness brand, Dogsee Chew, made a landmark debut at the 79th edition of the Cannes Film Festival on May 16, 2026, becoming one of the first Indian pet wellness brands to represent the industry on one of the world’s most prestigious global platforms.

 

Representing the brand at Cannes were co-founders and pet parents Sneh Sharma and Bhupendra Khanal, whose powerful red carpet appearance highlighted the growing cultural and global significance of pet wellness. As pets increasingly become integral members of families worldwide, conversations around natural nutrition, preventive care, wellness, and mindful pet parenting are rapidly entering mainstream lifestyle and consumer spaces.

 

Founded in 2015, Dogsee Chew pioneered the Himalayan yak chew category globally with its natural Chhurpi-based dog treats sourced from the Himalayas. Today, the Bengaluru-based company is present in over 30 countries and trusted by more than a million pet parents worldwide for its preservative-free, rawhide-free, and natural pet nutrition offerings.

 

What made the Cannes appearance especially emotional was the founders’ heartfelt tribute to their late dog, Mowgli — the inspiration behind Dogsee Chew’s journey. The theme of their red carpet appearance, titled “An Ode To Mowgli,” beautifully blended emotion, fashion, and Himalayan heritage.

 

Sneh Sharma wore a custom ensemble by Indian label Duchess Kumari, paired with jewellery from Kushal Fashion Jewellery. Her outfit featured intricate Himalayan-inspired detailing along the hem symbolising the brand’s roots, while the corset carried an embroidered motif of Mowgli. Bhupendra Khanal wore a custom suit by Twamev featuring Mowgli’s embroidered motif on the left chest — a subtle yet deeply emotional tribute to the dog who inspired the company’s vision.

 

Speaking about the moment, Sneh Sharma, Co-founder, Dogsee Chew, said, “Walking the Cannes red carpet was an incredibly emotional and proud moment for us. Mowgli was not just our pet, but the soul behind Dogsee’s journey. Through this tribute, we wanted to celebrate the unconditional love pets bring into our lives while also representing India, the Himalayas, and the growing global conversation around pet wellness on such an iconic platform.”

 

Bhupendra Khanal, Co-founder, Dogsee Chew, added, “For us, Cannes is much bigger than a red carpet moment. It represents how far the pet wellness industry has evolved globally. Seeing a Himalayan-born Indian brand being recognised on an international stage reinforces the growing importance of conscious pet parenting, natural nutrition, and wellness-led lifestyles worldwide. Carrying Mowgli’s memory with us made this moment deeply personal and unforgettable.”

 

Dogsee Chew’s presence at Cannes also reflects the larger transformation taking place within the global pet care industry. Once considered a niche segment, pet wellness has rapidly emerged as one of the world’s fastest-growing consumer categories, driven by increasing awareness around animal health, preventive care, and premium nutrition.

 

Over the years, Dogsee Chew has expanded its portfolio beyond Himalayan Yak Chews into dental chews, training treats, puffed snacks, functional variants, and wellness supplements under its Dogsee Activet Plus+ range. As the company continues to strengthen its presence across India, the US, Canada, Europe, and the Asia-Pacific region, Dogsee Chew aims to position Himalayan natural nutrition as a global benchmark in pet wellness while building one of the world’s most trusted pet care brands from India.

 

YouTube Link: https://www.youtube.com/shorts/H7C0FbMm7P0

Business Wire India

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy

 

BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL

 

Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise

 

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA^® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI^™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL.

 

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:
“CLL is a disease patients live with for years, and the real measure of a therapy is how it performs over the long arc of treatment. Our data at ASCO show that BRUKINSA continues to deliver sustained disease control, which can give physicians and patients confidence to stay the course. Additionally, robust, real-world analyses reinforce its role as a best-in-class BTK inhibitor, with data favoring BRUKINSA over other BTK inhibitors across several efficacy and safety endpoints. With BRUKINSA as the foundation, we are building a broad, differentiated hematology franchise designed to push the field further, including our ZS combination, which achieved deep responses and unprecedented rates of uMRD, and emerging approaches like our BTK degrader, tacabrutideg. Together, these foundational therapies reflect our commitment to redefining what patients should expect from therapy both today and in the future.”

 

 

78-month SEQUOIA data highlight the long-term impact of first-line treatment choice in CLL (Poster Presentation: 544; June 1, 2026, 9:00 AM-12:00 PM CDT)
SEQUOIA now provides the longest reported follow-up for a next-generation BTK inhibitor in first-line CLL, enabling a deeper understanding of how treatment outcomes evolve over time. After a median follow-up of 84.01 months (range, 0.0-101.5), BRUKINSA continued to show benefit over bendamustine-rituximab (BR) in patients with treatment-naive CLL/SLL, with progression-free survival (PFS) outcomes that are unprecedented among BTK inhibitors. Key highlights include:

 

 

• 78-month PFS: 71.8% (95% CI, 65.3-77.3) for BRUKINSA vs. 31.0% (95% CI, 24.3-37.9) for BR
• 78-month COVID-adjusted PFS: 74.6% (95% CI, 68.1-79.9) for BRUKINSA vs. 31.4% (95% CI, 24.7-38.4) for BR
  • PFS for patients with unmutated IGHV: 70.4% (95% CI, 61.0-77.9) for BRUKINSA vs. 17.4% (95% CI, 9.6-27.1) for BR
  • PFS for patients with mutated IGHV: 81.8% (95% CI: 72.2-88.4) for BRUKINSA and 45.1% (95% CI: 34.4-55.2) for BR
• 78-month PFS2: 81.3% (95% CI, 75.6-85.8) for BRUKINSA vs. 74.4% (95% CI, 67.8-79.8) for BR
• 78-month COVID-adjusted PFS2: 84.7% (95% CI, 79.2-88.8) for BRUKINSA and 76.4% (95% CI, 69.9-81.7) for BR
  • Of the BRUKINSA-treated patients who progressed (26/241), half received subsequent therapy with BCL2 inhibitor-based salvage therapy and 69.2% had not progressed after more than 3 years of follow-up.
• Time to next treatment (TTNT) favored BRUKINSA over BR (HR, 0.24; 95% CI, 0.16-0.35; P<.0001)
• Safety: consistent with the results of prior BRUKINSA studies with no new safety signals.

 

 

PFS2 captures outcomes beyond first disease progression, measuring time to disease progression on subsequent therapy or death. In CLL, this endpoint provides important insight into how first-line treatment impacts long-term disease control across multiple lines of therapy.

 

Constantine Tam, M.B.B.S., M.D., Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University, said:
“In an indolent disease like CLL, many patients value maintaining disease control over the course of their life, not just in the first year or two of treatment. The continued long-term follow-up from SEQUOIA shows that zanubrutinib can deliver sustained disease control. This is the kind of evidence that allows clinicians and patients to make first-line decisions with real confidence about what lies ahead.”

 

 

Real-world efficacy and safety data consistently underscore foundational BRUKINSA as the best-in-class BTKi for TN CLL (Poster Presentations: 545, 543 and 540; June 1, 2026, 9:00 AM-12:00 PM CDT)
In addition to the update from SEQUOIA, BeOne will present data from new analyses of large and robust datasets, which demonstrate consistent and significant real-world benefits of using BRUKINSA over other BTK inhibitors. Key highlights include:

 

 

• In a real-world analysis of 10,523 Medicare patients, who were diagnosed with CLL/SLL and received frontline treatment with a BTK inhibitor, patients treated with BRUKINSA had a statistically significantly lower risk of death, advancing to next line, or discontinuing treatment, than those on ibrutinib or acalabrutinib. Similar results were observed across age subgroups. (Poster Presentation: 545)
• In a separate real-world analysis of Komodo database claims from 16,788 patients with treatment-naïve CLL, BRUKINSA had a longer TTNT (unadjusted HR, 0.88; 95% CI, 0.79-0.97; P=.009) and overall survival (OS; HR, 0.72; 95% CI, 0.62-0.82; P<.001). (Poster Presentation: 543)
• A retrospective analysis of 233,362 newly diagnosed CLL patients who initiated treatment with a BTK inhibitor, the atrial fibrillation rate within 1 year was lowest for BRUKINSA at 11% and 13% for acalabrutinib and 16% for ibrutinib (overall P<.0001). (Poster Presentation: 540)

 

 

Deep, rapid responses with BRUKINSA plus sonrotoclax (ZS) point to the future of time-limited treatment in CLL, including high-risk disease (Poster Presentation: 541; June 1, 2026, 9:00 AM-12:00 PM CDT)
In the Phase 1/1b study in patients with treatment-naïve CLL/SLL (median follow-up of ~34 months), the all-oral combination of BRUKINSA and next-generation BCL2 inhibitor sonrotoclax (ZS) demonstrated unprecedented rates and kinetics of undetectable minimal residual disease (uMRD), including in patients with high-risk cytogenetics. Key highlights include:

 

• Overall response rate (ORR): 100%, with complete responses in 59.5% of patients
• Best uMRD4 rate 98.8%
  • No patient that achieved uMRD4 reverted to uMRD positivity.
• Best uMRD in patients with TP53 mutation/del(17p): 92.9% across 2 dose levels
• Median time from combination start to uMRD4: 4.5 months
• No disease progression events observed at the recommended Phase 2 dose of 320mg, including patients who electively discontinued therapy
• Safety: consistent with previously reported BRUKINSA and sonrotoclax combination studies.

 

 

These data will also be presented as encore presentations at the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm) along with more than 30 other data sets from BeOne.

 

About BRUKINSA^® (zanubrutinib)
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

 

 

With the broadest label globally, BRUKINSA is the foundational BTK inhibitor and is the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing.

 

 

The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.

 

 

About BEQALZI^™ (sonrotoclax)
BEQALZI^™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. Sonrotoclax has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,500 patients have been enrolled across the broad sonrotoclax global development program.

 

 

BEQALZI is approved by the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a BTK inhibitor. It is also approved in China for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy, including a BTK inhibitor.

 

 

About Tacabrutideg (BGB-16673)
Tacabrutideg is a foundational and potential first-in-class and best-in-class orally available Bruton’s tyrosine kinase (BTK) degrader. With 1,200+ patients dosed to date in an extensive global clinical development program, tacabrutideg is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, tacabrutideg is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.

 

 

The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to tacabrutideg for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted tacabrutideg PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

 

 

Select Important Safety Information for BRUKINSA
Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).

 

 

In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

 

 

Please see full U.S. Prescribing Information including U.S. Patient Information.

 

 

Select Important Safety Information for BEQALZI^™ (sonrotoclax)
Serious and sometimes fatal adverse reactions have occurred with BEQALZI, including tumor lysis syndrome (TLS), serious infections, neutropenia, and embryo-fetal toxicity. BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome.

 

 

In the safety population (N=115), tumor lysis syndrome occurred in 7% of patients who followed the recommended dose ramp-up. Serious infections occurred in 14% of patients, and Grade 3 or 4 infections occurred in 17% (fatal: 2.6%), with pneumonia (10%) being the most common Grade 3 or greater infection. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%), and febrile neutropenia occurred in 1.7% of all patients. The most common adverse reactions (≥15%) were pneumonia (16%) and fatigue (16%). The most common Grade 3–4 laboratory abnormalities (≥15%) were decreases in lymphocytes (29%) and neutrophils (18%).

 

 

Please see full Prescribing Information.

 

 

The information provided in this press release is intended for a global audience. Product indications vary by region.

 

 

About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential patient benefits of zanubrutinib, sonrotoclax and tacabrutideg; BeOne’s ability to redefine what patients should expect from therapy; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit our Newsroom.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529392296/en/

 

Business Wire India

Charoen Pokphand Foods Public Company Limited (CPF) and FPT Corporation (FPT) recently signed a Memorandum of Understanding (MoU) for a strategic cooperation in Vietnam between CPF and FPT to advance AI-led and digital transformation in agri-food value chains, with the focus on agriculture, food processing, smart manufacturing, and supply chain management in Vietnam.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529529814/en/

 

 

 

The MoU exchange ceremony took place at the Thailand-Vietnam Business Forum 2026, held on May 28, 2026, in Bangkok. The event was attended by the Prime Minister of the Kingdom of Thailand, H.E. Anutin Charnvirakul, and the Vietnam Party General Secretary and State President, H.E. To Lam, commemorating the 50th Anniversary of Vietnam–Thailand Diplomatic Relations (1976–2026) under the theme “Growing Together,” highlighting Vietnam’s strategic commitment to technology-driven growth.

 

Under the agreement, C.P. Vietnam Corporation (C.P. Vietnam), a subsidiary under CPF and Vietnam’s leading integrated agri-food corporation, and FPT will explore the development and deployment of AI and digital solutions across C.P. Vietnam’s integrated Feed-Farm-Food value chain, from farm to family, and supply chain networks, from 2026 to 2028 and beyond.

 

 

The scope of cooperation covers strategic areas including Smart Camera and AI Vision, Smart Scales and Customer Experience, Smart Manufacturing and Smart Supply Chain, Industrial Internet of Things (IIoT) platforms, Centralized Data Integration, Agentic AI for Operational Intelligence, Food Safety and Traceability, and Smart Farm Model and Farmer Ecosystem Expansion.

 

 

In the pilot phase, both sides will establish Smart Farm models at selected C.P. Vietnam facilities, targeting about 20% reduction in operational costs and 100% food safety traceability. The ambition is to turn the Smart Farm model into a practical engine for wider transformation, bringing FPT’s AI solutions into more C.P. Vietnam facilities and across its contract farmer network. This can create a pathway for Smart Farm and AI AgriTech solutions to reach farmers nationwide, supporting Vietnam’s broader agricultural modernization agenda.

 

 

“With our AI-first strategy and proven capabilities in supporting global manufacturers, FPT will cooperate with C.P. to build a smarter, more connected, and resilient agri-food ecosystem, moving towards AI-enabled smart agriculture while adding value to all of its stakeholders. This partnership reflects a broader opportunity for Vietnam and Thailand to harness next-generation technologies to drive regional impact, strengthen food security, and sustain the growth and competitiveness of Southeast Asia’s agricultural value chains,” said Levi Nguyen, Chief Executive Officer of FPT Thailand and FPT Taiwan, FPT Corporation.

 

 

“C.P. Vietnam supports the Vietnam–Thailand Comprehensive Strategic Partnership Action Program 2026–2030, which promotes economic cooperation, investment, technology transfer, and digital transformation. Through this cooperation with FPT, we look forward to leveraging digital transformation across C.P. Vietnam’s integrated Feed–Farm–Food value chain, from farm to family. C.P. Vietnam continues its efforts to become a trusted partner in shaping the sustainable future of Vietnam’s agri-food industry and nurturing life by delivering safe, high-quality offerings through innovative and sustainable practices,” said Pawalit Ua-amornwanit, Chief Executive Officer of C.P. Vietnam.

 

 

Since its establishment, FPT has become a trusted technology partner for more than 500 enterprises in the Asia Pacific, helping enterprises modernize complex operations and accelerate digital transformation at scale. With Thailand among the key regional markets, the company serves leading enterprises across banking and finance, insurance, retail, automotive, manufacturing, healthcare, energy and utilities, consumer goods, and aviation, with clients and partners including Unilever, Central Group, AIA, LMG, Prudential, KBTG, SCB, KKP, TTB, FWD, Honda, Panasonic, Mitsubishi, Hitachi, Microsoft and Sunline. As a co-founder of the Vietnam–Thailand Chamber of Commerce (VietCham Thailand), the company also plays an active role in strengthening bilateral cooperation.

 

 

About FPT

 

 

FPT Corporation (FPT) is a globally leading Vietnam-headquartered technology and IT services provider, with operations spanning more than 30 countries and territories. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. With a strong focus on mastering strategic technologies, FPT continues to drive innovation across industries. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses.
For more information about FPT’s global IT services, please visit https://fptsoftware.com.

 

 

About C.P. Vietnam Corporation

 

 

C.P. Vietnam Corporation, a member of Charoen Pokphand Group, has been operating in Vietnam since 1993. Today, C.P. Vietnam is one of the leading agri-food corporations in Vietnam, operating an integrated Feed – Farm – Food business model in accordance with international standards to deliver high-quality and sustainable food solutions from farm to family.

 

 

Sustainability is embedded at the core of C.P. Vietnam’s business strategy and is driven through three key commitments: climate protection, improving quality of life, and advancing sustainable food systems. C.P. Vietnam is working toward its goal of achieving net-zero emissions by 2050, while continuing to expand renewable energy adoption and strengthen responsible resource management across its operations.

 

 

C.P. Vietnam currently operates 12 animal feed mills, 2 pork slaughterhouses, and 6 food processing plants, including one of Southeast Asia’s most advanced integrated chicken processing complex for export, alongside a nationwide network of modern farms across multiple provinces and cities.

 

 

Throughout more than three decades of operations in Vietnam, C.P. Vietnam has remained steadfast in its “Three Benefits Principle”, placing the benefits of the country and its people at the center of its values. C.P. Vietnam continuously strives to be the trusted partner in shaping the sustainable future of agri-food industry.

 

 

For more information about C.P. Vietnam, please visit https://www.cp.com.vn

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260529529814/en/

 

Business Wire India

Citi will host its flagship India Conference 2026 on June 3 & 4 at the Jio World Convention Centre, Mumbai. As the largest event on Citi’s annual India calendar, the conference will convene more than 1,000+ clients, 40+ CXOs, and 120+ corporates, representing a combined market capitalization of approximately US$1.8 trillion. Bringing together leaders from across the corporate and financial ecosystem, the conference will create opportunities for engagement through discussions, networking and knowledge-sharing.

The two-day event will serve as a platform for examining the forces reshaping business, investment and economic activity in India and globally. The sessions will cover a range of topics including the macroeconomic outlook, policy environment, capital markets, emerging investment trends, artificial intelligence, digital infrastructure and innovation.

Amol Gupte, Citi’s Asia South Cluster & Banking Head, said: “The Citi India Conference puts a spotlight on India’s significant and growing role in the world economy and reflects the confidence that global investors and businesses place in India’s future. As we approach 125 years of Citi’s presence in India next year, we are proud to continue to connect India’s most ambitious corporates to global opportunities and multinational companies to opportunities in India — and this conference sits right at the heart of that journey.”

 

K Balasubramanian, India CEO & Banking Head and Indian Subcontinent Sub-Cluster Head, Citi, said: “Citi is delighted to host Government dignitaries, senior clients, key investors and thought leaders to this Conference which is expected to unlock the value of India as an investment destination and provide investors an opportunity to take part in the long-term growth narrative amidst a volatile market. 

 

As the world’s most global bank, with our leading institutional banking platform in India, Citi connects cross-border perspectives, strategic capital and transformative ideas. This conference is a natural extension of that commitment. We hope every participant leaves with new perspectives, stronger connections and a deeper conviction in the India opportunity.”

 

The Citi India Conference reflects Citi’s longstanding commitment to supporting clients through deep market expertise, global connectivity and access to strategic opportunities across markets.

Business Wire India

KASIKORNBANK (KBank) and Ant International have formed a strategic collaboration to jointly develop an integrated financial infrastructure to deliver faster, more reliable, and scalable payment experiences for Ant International and its customers.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528577525/en/

 

 

 

The Memorandum of Understanding (MoU) will combine KBank’s regulated financial capabilities with Ant International’s financial AI solutions to enable real-time, 24/7¹ cross-border USD transactions. The initiative will leverage Blockchain Deposit Accounts from Kinexys by J.P. Morgan, the industry-leading blockchain business part of J.P. Morgan Payments for real-time USD liquidity movement and is expected to significantly enhance transaction speed while enabling continuous 24/7² operations. KBank and Ant International will also use their best efforts to develop end-to-end solutions across payment acceptance, clearing, and settlement. These advancements remain subject to all necessary legal and regulatory approvals.

 

This collaboration will enhance Ant International’s inbound and outbound transaction and settlement efficiency, thus improving the business cashflow of the merchants the company serves.

 

 

This partnership builds on KBank’s existing collaboration with Ant International’s global payment services. Through Alipay+, Ant International’s digital wallet gateway, KBank’s mobile banking app KPLUS is connected into an ecosystem of 150 million merchants and 1.8 billion consumer accounts worldwide. KPLUS is also a growing payment option on Google Pay for Thai merchants through its integration with Antom, Ant International’s merchant payment service.

 

 

Dr. Karin Boonlertvanich, Executive Vice President of KASIKORNBANK, said, “This collaboration addresses a fundamental limitation in today’s cross-border financial systems, where liquidity movement remains constrained by fragmented infrastructure. By integrating blockchain with regulated financial systems, we are enabling a more continuous, transparent, and scalable flow of funds between global networks and local economies.”

 

 

Kelvin Li, General Manager of Platform Tech and Senior Vice President at Ant International, said, “Across emerging markets, industry leaders like KBank are preparing communities for a more interconnected global economy with broader and more secure application of AI and blockchain technology. We are thrilled to support KBank with such fintech solutions to empower Thai merchants – especially small businesses – with more efficient payment tools to thrive globally.”

 

 

This MOU underscores a shared commitment to the development of integrated and scalable cross-border financial systems, enhancing the efficiency and reliability of global payment systems for international commerce.

 

 

The development and potential implementation of this initiative will be undertaken in consultation with the relevant regulatory authorities, and will be subject to obtaining the necessary approvals prior to any live service deployment.

 

 

About KASIKORNBANK

 

 

KASIKORNBANK PUBLIC COMPANY LIMITED (KBank) operates under the vision of being a “Bank of Sustainability”, dedicated to delivering long-term value to all stakeholders through innovation, strong governance, and responsible growth. KBank continues to strengthen its leadership in digital banking through strategic initiatives that drive financial inclusion and cross-border interoperability, including the development of blockchain-based infrastructure and regulated on-chain payment ecosystems in partnership with global innovators.

 

 

About Ant International

 

 

Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/

 

 

1 Transfers on the network are completed on a 24/7/365 and same day basis. Moving funds to and from the network from traditional Demand Deposit Accounts on legacy systems to Blockchain Deposit Accounts has a three- hour downtime over the weekend (3-6 p.m. EST every Saturday.) Enhancement is under development.
2 Transfers on the network are completed on a 24/7/365 and same day basis. Moving funds to and from the network from traditional Demand Deposit Accounts on legacy systems to Blockchain Deposit Accounts has a three- hour downtime over the weekend (3-6 p.m. EST every Saturday.) Enhancement is under development.

 

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528577525/en/